215 related articles for article (PubMed ID: 22527251)
21. Cryopreserved leukapheresis material can be transferred from controlled rate freezers to ultracold storage at warmer temperatures without affecting downstream CAR-T cell culture performance and in-vitro functionality.
Wei J; Chaney K; Shim WJ; Chen H; Leonard G; O'Brien S; Liu Z; Jiang J; Ulrey R
Cryobiology; 2024 Jun; 115():104889. PubMed ID: 38513998
[TBL] [Abstract][Full Text] [Related]
22. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application.
Thurner B; Röder C; Dieckmann D; Heuer M; Kruse M; Glaser A; Keikavoussi P; Kämpgen E; Bender A; Schuler G
J Immunol Methods; 1999 Feb; 223(1):1-15. PubMed ID: 10037230
[TBL] [Abstract][Full Text] [Related]
23. Issues concerning the large scale cryopreservation of peripheral blood mononuclear cells (PBMC) for immunotherapy trials.
Best A; Hidalgo G; Mitchell K; Yannelli JR
Cryobiology; 2007 Jun; 54(3):294-7. PubMed ID: 17433284
[TBL] [Abstract][Full Text] [Related]
24. Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical use.
Gülen D; Maas S; Julius H; Warkentin P; Britton H; Younos I; Senesac J; Pirruccello SM; Talmadge JE
Int Immunopharmacol; 2012 May; 13(1):61-8. PubMed ID: 22465385
[TBL] [Abstract][Full Text] [Related]
25. In vitro generation of dendritic cells derived from cryopreserved CD34+ cells mobilized into peripheral blood in lymphoma patients.
Enomoto M; Nagayama H; Sato K; Xu Y; Asano S; Takahashi TA
Cytotherapy; 2000; 2(2):95-104. PubMed ID: 12042046
[TBL] [Abstract][Full Text] [Related]
26. Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction.
John J; Hutchinson J; Dalgleish A; Pandha H
J Immunol Methods; 2003 Jan; 272(1-2):35-48. PubMed ID: 12505710
[TBL] [Abstract][Full Text] [Related]
27. Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy.
Elias M; van Zanten J; Hospers GA; Setroikromo A; de Jong MA; de Leij LF; Mulder NH
J Clin Apher; 2005 Dec; 20(4):197-207. PubMed ID: 15892082
[TBL] [Abstract][Full Text] [Related]
28. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.
Wong EC; Maher VE; Hines K; Lee J; Carter CS; Goletz T; Kopp W; Mackall CL; Berzofsky J; Read EJ
Cytotherapy; 2001; 3(1):19-29. PubMed ID: 12028840
[TBL] [Abstract][Full Text] [Related]
29. Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity.
Sloan AE; Parajuli P
J Neurooncol; 2003; 64(1-2):177-83. PubMed ID: 12952298
[TBL] [Abstract][Full Text] [Related]
30. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
Michiels A; Tuyaerts S; Bonehill A; Corthals J; Breckpot K; Heirman C; Van Meirvenne S; Dullaers M; Allard S; Brasseur F; van der Bruggen P; Thielemans K
Gene Ther; 2005 May; 12(9):772-82. PubMed ID: 15750615
[TBL] [Abstract][Full Text] [Related]
31. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.
Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Cytotherapy; 2006; 8(4):318-26. PubMed ID: 16923607
[TBL] [Abstract][Full Text] [Related]
32. T cell responses in fresh and cryopreserved peripheral blood mononuclear cells: kinetics of cell viability, cellular subsets, proliferation, and cytokine production.
Jeurink PV; Vissers YM; Rappard B; Savelkoul HF
Cryobiology; 2008 Oct; 57(2):91-103. PubMed ID: 18593572
[TBL] [Abstract][Full Text] [Related]
33. Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells.
Parajuli P; Mathupala S; Sloan AE
Neurosurgery; 2004 Nov; 55(5):1194-204. PubMed ID: 15509326
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of using monocyte-derived dendritic cells obtained from cryopreserved cells for DC-based vaccines.
Usero L; Miralles L; Esteban I; Pastor-Quiñones C; Maleno MJ; Leal L; García F; Plana M
J Immunol Methods; 2021 Nov; 498():113133. PubMed ID: 34480950
[TBL] [Abstract][Full Text] [Related]
35. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.
Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ
Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436
[TBL] [Abstract][Full Text] [Related]
36. Cryopreservation of bovine mononuclear leukocytes.
Kleinschuster SJ; VanKampen KR; Spendlove R; Atluru D; Zupancic ML; Muscoplat CC
Am J Vet Res; 1979 Nov; 40(11):1649-51. PubMed ID: 316656
[TBL] [Abstract][Full Text] [Related]
37. Preservation of cell-based immunotherapies for clinical trials.
Li R; Johnson R; Yu G; McKenna DH; Hubel A
Cytotherapy; 2019 Sep; 21(9):943-957. PubMed ID: 31416704
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the effect of cryoprotectant medium composition to viability of autologous hematopoietic cells collected by leukapheresis.
Kozlowska-Skrzypczak M; Kubiak A; Bembnista E; Matuszak P; Komarnicki M
Transplant Proc; 2014 Oct; 46(8):2535-8. PubMed ID: 25380858
[TBL] [Abstract][Full Text] [Related]
39. Phenotypical and functional characterization of clinical grade dendritic cells.
de Vries IJ; Eggert AA; Scharenborg NM; Vissers JL; Lesterhuis WJ; Boerman OC; Punt CJ; Adema GJ; Figdor CG
J Immunother; 2002; 25(5):429-38. PubMed ID: 12218781
[TBL] [Abstract][Full Text] [Related]
40. Single step enrichment of blood dendritic cells by positive immunoselection.
López JA; Bioley G; Turtle CJ; Pinzón-Charry A; Ho CS; Vuckovic S; Crosbie G; Gilleece M; Jackson DC; Munster D; Hart DN
J Immunol Methods; 2003 Mar; 274(1-2):47-61. PubMed ID: 12609532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
